| 000 | 01833 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516030819.0 | ||
| 264 | 0 | _c20110902 | |
| 008 | 201109s 0 0 eng d | ||
| 022 | _a1872-7549 | ||
| 024 | 7 |
_a10.1016/j.bbr.2011.03.027 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSvalbe, Baiba | |
| 245 | 0 | 0 |
_aMildronate treatment improves functional recovery following middle cerebral artery occlusion in rats. _h[electronic resource] |
| 260 |
_bBehavioural brain research _cSep 2011 |
||
| 300 |
_a26-32 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xtherapeutic use |
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBetaine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aBrain Infarction _xetiology |
| 650 | 0 | 4 |
_aCarnitine _xmetabolism |
| 650 | 0 | 4 |
_aChromatography, High Pressure Liquid _xmethods |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aExtremities _xphysiopathology |
| 650 | 0 | 4 |
_aInfarction, Middle Cerebral Artery _xdrug therapy |
| 650 | 0 | 4 |
_aLocomotion _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethylhydrazines _xtherapeutic use |
| 650 | 0 | 4 |
_aPsychomotor Performance _xdrug effects |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 |
_aRecovery of Function _xdrug effects |
| 650 | 0 | 4 | _aRotarod Performance Test |
| 650 | 0 | 4 |
_aTandem Mass Spectrometry _xmethods |
| 650 | 0 | 4 |
_aVibrissae _xinnervation |
| 700 | 1 | _aZvejniece, Liga | |
| 700 | 1 | _aVavers, Edijs | |
| 700 | 1 | _aPugovics, Osvalds | |
| 700 | 1 | _aMuceniece, Ruta | |
| 700 | 1 | _aLiepinsh, Edgars | |
| 700 | 1 | _aDambrova, Maija | |
| 773 | 0 |
_tBehavioural brain research _gvol. 222 _gno. 1 _gp. 26-32 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bbr.2011.03.027 _zAvailable from publisher's website |
| 999 |
_c20690894 _d20690894 |
||